ScreenerHero

CTMXCytomX Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · cytomx.com
3.280USD-8.12%Mkt Cap: 714.71M $P/E: —

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platfo…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0
HeadlineSourceTime
Older
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ...

Strong clinical progress and expanded Regeneron collaboration bolster CytomX's path forward despite revenue decline and safety considerations.

GuruFocus.com
CytomX Therapeutics Q2 Earnings Call Highlights

CytomX Therapeutics (NASDAQ:CTMX) said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers. Chief Executiv

MarketBeat
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +18.18% and -80.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
Zacks
Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?
IInsider Monkey
How The Narrative Around CytomX Therapeutics (CTMX) Is Evolving With Recent Developments
Simply Wall St.
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
Simply Wall St.
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
Zacks
Why Regeneron (REGN) Stock Is Trading Up Today
SStockStory
CytomX (CTMX) Q4 2025 Earnings Transcript
Motley Fool
How The CytomX Therapeutics (CTMX) Story Is Shifting With New Colorectal Cancer Data And Risks
Simply Wall St.